Humanized anti-beta7 antagonists and uses therefor
AssigneeGenentech, Inc.
InventorsSherman Fong, Mark Dennis
Life of this patent
Estimating the term…
Abstract
The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
Claims7
1-53. (canceled)
An anti-beta7 antibody comprising:
- an HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each, in order, comprises RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), and RTGSSGYFDF (SEQ ID NO:66).
55-60. (canceled)
A method of inhibiting the interaction of a human beta7 integrin subunit with a second integrin subunit and/or a ligand by contacting a humanized anti-beta7 antibody with the beta7 integrin.
A method of modulating beta7 integrin-mediated cellular adhesion and/or recruitment in a human experiencing a disorder by administering to the mammal an effective amount of a composition comprising a humanized anti-beta7 antibody and a pharmaceutical carrier.
Dependencies are inferred from the claim text.